"Hemophilia is an inherited bleeding disorder in which the blood does not clot normally because of a missing or dysfunctional clotting protein. Clotting proteins, also called clotting factors, work with other blood components such as platelets, von Willebrand factor, and other proteins to form a blood clot. When any of these components is absent or low, increased bleeding can result. If clotting factor VIII (8) or factor IX (9) are affected, this bleeding disorder is called hemophilia."

During the past decade, Boston Hemophilia Center at Children's Hospital of Boston conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Boston Hemophilia Center at Children's Hospital of Boston" #1 collaborator was "CSL Behring" with 2 trials as a collaborator, "Bayer" with 1 trials as a collaborator, "Bioverativ Therapeutics Inc." with 1 trials as a collaborator, "Octapharma" with 1 trials as a collaborator and "Shire" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Boston Hemophilia Center at Children's Hospital of Boston" are "Hemophilia" (2 trials), "Haemophilia" (1 trials), "Haemophilia A Without Inhibitor" (1 trials), "Haemophilia B Without Inhibitor" (1 trials) and "Hemophilia A" (1 trials). Many other conditions were trialed in "Boston Hemophilia Center at Children's Hospital of Boston" in a lesser frequency.

Most popular intervention types in "Boston Hemophilia Center at Children's Hospital of Boston" are "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Factor IX Replacement Products for Hemophilia which were FDA approved after January 1, 2013" (1 trials) and "Factor VIII Replacement Products for Hemophilia which were FDA approved after January 1, 2013" (1 trials). Other intervention names were less common.

The vast majority of trials in "Boston Hemophilia Center at Children's Hospital of Boston" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Boston Hemophilia Center at Children's Hospital of Boston". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Boston Hemophilia Center at Children's Hospital of Boston, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Boston Hemophilia Center at Children's Hospital of Boston, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".